


 Cite this: *RSC Adv.*, 2026, 16, 14092

Rational design and synthesis of non-competitive transcription inhibitors targeting a conserved RNA polymerase- σ^A interface

 Mukesh Tandi,^a Nilima Hati,^b Mukul Kore,^a Debashree Behera,^b Twinkal Patel,^b Eeba,^c Nisheeth Agarwal,^c Balasubramanian Gopal^{b,cd} and Sandeep Sundriyal^{b,ea}

RNA polymerase (RNAP) inhibitors that block RNA chain elongation or disrupt DNA unwinding have long served as frontline therapeutic agents. However, a major limitation of competitive inhibitors like rifampicin is the rapid emergence of resistance due to point mutations at the RNAP active site. Transcription initiation, the first step in mRNA synthesis, depends on the interaction between RNAP and a sigma (σ) factor. We targeted the conserved region of the RNAP- σ^A interaction interface to inhibit transcription initiation. *Mycobacterium tuberculosis* σ^A was used as a template for inhibitor design due to the extensive experimental structural data on *Mycobacterial* RNAP in the apo and holo forms, with a promoter DNA fragment, as well as complexes with rifampicin and $N\alpha$ -aroyl-*N*-aryl-phenylalaninamide inhibitors. Sequence comparison and subsequent mutational analysis validated Asp319, Glu322, and Gln323 in *M. tuberculosis* σ^A as critical residues for interaction with the RNAP β' subunit. The interface encompassing this polypeptide segment served as a target for inhibitor design. Structure-based virtual screening (SBVS) of a Ugi reaction derived library (URDL) led to the identification of hydroxamate **2a** that could bind to *M. tuberculosis* σ^A (K_D 2.8 μ M). Systematic exploration of SAR via 22 analogues led to non-hydroxamate **2u** as a superior binder (K_D 0.9 μ M). Both **2a** and **2u** also displayed almost complete inhibition of transcription at 1 mM. In a whole-cell bactericidal assay, **2u** exhibited clear bactericidal activity against *Staphylococcus aureus* (MIC 50 μ M) and *M. tuberculosis* (MIC 250 μ M). Overall, this study showcases the rational design of non-competitive inhibitors of *M. tuberculosis* transcription through a systematic application of *in silico* screening and multicomponent reaction chemistry.

Received 18th January 2026

Accepted 9th March 2026

DOI: 10.1039/d6ra00442c

rsc.li/rsc-advances

1. Introduction

The transcription mechanism is essential for bacterial survival. The multi-subunit RNA polymerase enzyme driving this mechanism is widely conserved across bacteria. The structure of bacterial RNAPs is widely conserved despite differences in amino acid sequences across RNAP homologues. Transcription initiation, the first step of transcription, involves the recruitment of the RNAP enzyme to the promoter DNA. This step, which primarily serves as the checkpoint regulating gene expression, can vary across bacterial species.¹ For example, in the case of *M. tuberculosis*, when compared to the well-characterized *Escherichia coli* RNAP, the open promoter RNAP-

σ^A (holoenzyme) complex is inherently unstable and requires accessory proteins like the RNAP-binding protein A (RbpA) and Caspase recruitment domain (CarD) for transcript formation.² Several other protein factors, like WhiB, modulate RNAP activity under specific environmental stress conditions. Indeed, *M. tuberculosis* RNAP has been better explored for development of inhibitors than RNAP from other bacterial pathogens.³ These insights have been compiled in a recent review that also provides a summary of all the antimycobacterial compounds developed against the RNAP enzyme, specifically targeting the transcription initiation step.⁴ To date, peptides and small molecules have been designed to target the base clamp region in the β subunit, the switch region and bridge helix in the β' subunit, and the RNAP active site. However, a major drawback of rifampicin and other competitive modulators against transcription or other essential cellular processes is the emergence of drug-resistant mutations.^{5,6} It is worth noting in this context that the RNAP- σ factor interface, located away from the active site, has not been extensively explored for inhibitor design despite significant structural conservation across bacterial homologues.

^aDepartment of Pharmacy, Birla Institute of Technology and Science Pilani, Pilani Campus, Rajasthan, 333031, India. E-mail: sandeep.sundriyal@pilani.bits-pilani.ac.in

^bMolecular Biophysics Unit, Indian Institute of Science, Bangalore, 560012, India. E-mail: bgopal@iisc.ac.in

^cBRIC-Translational Health Science and Technology Institute, NCR Biotech Science Cluster, 3rd Mile Stone, Gurugram-Faridabad Expressway, Faridabad 121001, Haryana, India

^dInstitute of Bioinformatics and Applied Biotechnology, Bangalore 560100, India



Targeting protein-protein interfaces is an emerging avenue for the design of non-competitive ligands in a variety of disease contexts despite several challenges.⁷⁻⁹ The interaction interface between the RNAP and a σ factor is well conserved across different bacteria and its disruption may result in transcription inhibition.¹⁰ Ma *et al.* utilized a homology model of the *Bacillus subtilis* RNAP β' - σ factor interface to develop a pharmacophore model to obstruct RNAP- σ factor binding. The pharmacophore model was used to screen an in-house library of peptidomimetic compounds to obtain inhibitors of RNAP β' - σ factor interactions. One of the bisindole derivatives, GKL003, was found to bind RNAP β' and inhibit the initiation of complex formation. The compound was also found to inhibit transcription and bacterial growth *in vitro*, thus validating the RNAP β' - σ factor interface as a druggable target.¹¹ Based on the new structural information, the authors further modified this pharmacophore model and discovered compound C5 from a commercial library that could inhibit transcription initiation *in vitro* and showed antibacterial activity.¹² Recently, the same group developed triaryl derivatives binding to the RNAP β' clamp helix region- σ interface and successfully demonstrated their activity against *Streptococcus pneumoniae*.¹³ These results demonstrate the validity of computational design for developing small molecule inhibitors of bacterial RNAP β' - σ factor interactions and subsequent disruption of transcription. Here we describe an approach towards structure-guided protein-protein interface inhibitors

focussing on the rigid stretch of σ^{70} that is occluded upon binding the RNAP β' subunit. We hypothesize that these inhibitors would obstruct recruitment of the RNAP apo-enzyme to the promoter DNA itself, thereby preventing transcription initiation.

The Pribnow box interacting domain (σ_2) of σ factors belonging to the σ^{70} family share significant commonality in the RNAP interaction interface. We utilized the *M. tuberculosis* β' and σ_2 interface (in particular with the primary, essential σ factor σ^A) for the ligand strategy thus building upon the extensive structural information on the Mycobacterial RNAP complexes with multiple experimentally determined structural models.¹⁴ A structure-based high throughput-virtual screening (HTVS) strategy was employed using the Ugi reaction-derived library (URDL) with high synthetic tractability that was reported by our laboratory earlier.¹⁵ The synthesis of hit molecules and SAR studies resulted in the identification of an experimentally validated scaffold that could be further developed for the design of non-competitive RNAP inhibitors.

2. Results and discussion

2.1 Identification and experimental validation of critical σ^A residues in RNAP interactions

Across multiple structural complexes, interactions between residues in the coiled-coil region of the β' domain and domain 2




Fig. 1 Identification of conserved residues on σ^A that form critical interactions at the RNAP β' - σ^A interface. (A) *M. tuberculosis* RNAP (PDB ID 5UH5) depicting key residues in the RNAP β' - σ^A interface (β' subunit shown in orange and σ^A shown in red). (B) Structure-based sequence alignment reveals the conservation of the residues of the target RNAP β' - σ^A interface across bacteria. (C) Structure-based sequence alignment of targeted residues in *M. tuberculosis* σ factors. (D) Validation of the target residues by *in vitro* transcription assay (please refer to the Experimental section for details).






Fig. 2 (A) RNAP β' - σ_2^A complex (PDB ID: 5UH5) in *M. tuberculosis* (B) conserved amino acids on σ_2^A (Chain F) crucial for binding RNAP β' domain. (C) Surface model representation of the interaction between 2a (Green sticks) and σ_2^A binding site. The solvent-accessible surface is color-coded based on the polarity (D) Intermolecular 3D Interactions between ligands 2a (Green sticks) and σ_2^A binding site residues.

of a σ factor were noted (Fig. 1A and B). For example, in *M. tuberculosis* σ_2^A , a cluster of four residues (Asp319, Glu322, Gln323 and Leu326) interact with β' residues (Arg350, Arg353, Leu357, Leu360, Asn369 and Glu370) (Fig. 1A). From this interface, conserved interacting residues among *M. tuberculosis* σ factors were identified by performing a structure-based sequence alignment using all *M. tuberculosis* σ factor sequences (Fig. 1B and C). To evaluate the significance of the target site of σ^A binding to the RNAP, residues that were considered crucial were evaluated by mutational analysis. The mutants of σ^A , including D319K, Q322K, E323K, and KKK (a triple mutant where all three residues- D319, Q322, and E323 were replaced by a positively charged residue, K) were examined. An *in vitro* transcription assay was performed with these mutants using the *M. tuberculosis* rRNA AP3 promoter. We note that the D319K mutant exhibited a relatively minor effect on


transcription activity, whereas the Q322K and E323K mutants showed no significant alteration in transcription. However, the triple mutant (KKK), encompassing all three mutations, demonstrated a notable and significant impact on transcriptional activity. These observations revealed that for *M. tuberculosis* σ^A mediated transcription, the interaction between σ^A residues Asp319, Glu322, and Gln323 with the β' domain is crucial. Thus, we hypothesized that small molecules binding to this region of *M. tuberculosis* σ^A could prevent RNAP- σ^A interaction leading to the inhibition of *M. tuberculosis* transcription.




2.2 Structure-based virtual screening (SBVS) against the identified σ^A site

Based on mutational analysis we selected a region around the residues Asp319, Glu322, and Gln323 of σ^A as the target site for



Table 1 Compounds with different substitutions at the P1 position of 2a



| ID | R | Docking score (kcal mol ⁻¹) | MMGBSA score (kcal mol ⁻¹) | Binding affinity K_D (μ M) |
|----|---|---|--|-----------------------------------|
| 2a | H | -4.239 | -64.28 | $2.8 \pm 0.8 \mu$ M |
| 2b |  | -0.225 | -67.07 | $237 \pm 181 \mu$ M |
| 2c |  | -4.269 | -91.73 | $0.124 \pm 84.0 \mu$ M |
| 2d |  | -3.679 | -60.14 | $0.699 \pm 0.487 \mu$ M |

the SBVS (PDB ID 5UH5, Fig. 2A). Earlier we reported a manually curated library of synthetically tractable molecules derived from the Ugi reaction (URDL) for virtual screening.^{15,16} The URDL molecules occupy property space of protein-protein inhibitors and provide an opportunity for the systematic exploration of multicomponent reactions in medicinal chemistry.^{17,18} These molecules are close to protein-protein inhibitors in chemical space and thus suitable for the given target. Moreover, most of the URDL molecules are drug-like and can be obtained in 1–2 synthetic steps under mild conditions.¹⁵ Thus, URDL is a suitable library for quick hit validation and SAR studies in the given scenario. The 5773 unique ligands in URDL were screened against *M. tuberculosis* σ^A structure (PDB ID 5UH5) employing the HTVS mode of the Schrodinger Suite to perform *in silico* screening (see SI). The hits were identified based on the docking scores and interactions with the conserved residues (Asp319, Glu322, and Gln323) found important for fostering interactions with RNAP. The hits were subsequently subjected to further analysis using the MMGBSA scoring.

This *in silico* screening resulted in structurally close hits among which compound 2a was found to be most promising (SI, Fig. S1) with a docking score of -4.01 kcal mol⁻¹ and a molecular mechanics with generalized born and surface area (MMGBSA) score of -64.28 kcal mol⁻¹ (Table 1). While the hydroxamate group of 2a displayed hydrogen bonding and non-classical hydrogen bond interactions with Gln322, Glu323, and Gln362 (Fig. 2C and D), the phenyl ring and *tert*-butyl groups of

2a remain solvent-exposed (Fig. 2C). The compound 2a was originally designed as a selective inhibitor of human histone deacetylase-6 (HDAC-6). However, it displayed weak inhibitory activity against HDAC-6 and low cytotoxicity.¹⁹ Compound 2a fulfilled the criteria to be included in URDL owing to its convenient two step synthesis through Ugi reaction. For the experimental validation, we synthesized 2a (over 95% purity by HPLC) and evaluated it for binding by Micro Scale Thermophoresis (MST). Pleasingly, 2a displayed a strong binding with




Fig. 3 Dose–response curve of binding between compound 2a and RbpA- σ_2^A complex.







Fig. 4 SAR plan around 2a. Ugi MCR allows the exploration of regions P1–P4 by employing diverse aldehydes, acid, isonitrile, and amine components.

σ^A with a dissociation constant (K_D) of $2.8 \pm 0.8 \mu\text{M}$ (Fig. 3), thus validating the computational design. These results encouraged us to carry out a SAR study for this series of compounds.

2.3 Chemistry

One of the reasons for using URDL was that the basic scaffold of these molecules could be assembled in a single-pot multicomponent reaction. Moreover, a series of analogues can be quickly generated by simply using a different set of building blocks.^{15–18} Accordingly, for the SAR study we planned to explore different regions P1–P4 of 2a scaffold arising from the four building blocks of the Ugi reaction (Fig. 4).

Initially, we followed the synthetic procedure reported in the literature report to obtain the intermediate 1a. Thus, a mixture of 4-aminomethyl benzoic acid methyl ester, formaldehyde, benzoic acid, and *tert*-butyl isocyanide was stirred at 15–25 °C, providing 1a with satisfactory yield (Scheme 1).¹⁹ The same method was used to obtain Ugi adducts 1b–1r from other



Scheme 1 Synthesis of derivatives of hit compound 2a. Reagents and conditions: (a) Et_3N , MeOH (anhydrous), molecular sieves 4 Å, N_2 , 15–25 °C, 48 h, (b) $\text{NH}_2\text{OH}\cdot\text{HCl}$, KOH, 0 °C, 4 h, (c) $\text{NH}_2\text{NH}_2\cdot\text{H}_2\text{O}$, EtOH, 6 h, reflux, (d) *O*-methylhydroxylamine hydrochloride, methanolic KOH, 0 °C, 4 h, (e) 7 N ammonia in MeOH, NaOMe, 25 °C, 24 h, (f) MeOH, H_2O , NaOH, 4 h, 25 °C.






Fig. 5 Comparison of the binding poses of 2a with (A) 2b, (B) 2c, and (C) 2d.

aldehydes, acids, and isocyanide components. The reported sodium methoxide-mediated hydroxyaminolysis, however, yielded unsatisfactory results with isolated yields up to 30% for the hydroxamates. Nonetheless, the usage of KOH base at low temperature worked well for the conversion of ester group to the desired hydroxamates (2a–2r) in good to satisfactory yields (Scheme 1).²⁰ Since the modeling studies implied an important role of hydroxamate function in forming H-bonds (Fig. 2D), we also synthesized analogues with alternative moieties at region P4. Thus, analogues 2s–2v were obtained from 1a using the appropriate nucleophiles, while acid derivative 2v was obtained by base-mediated hydrolysis of the ester 1a.

The purity ($\geq 95\%$) of all compounds was confirmed using reverse-phase HPLC. The 1D NMR spectra of most of the compounds revealed the presence of two sets of NMR signals due to the *cis-trans* amide bond rotamers (Fig. S3).^{19,21} It was further confirmed by performing NMR spectroscopy of 2a at a higher temperature (60 °C) which led to the merging peaks due to the rapid interconversion of two isomers. (SI, Fig. S2)

2.4. Modeling, binding studies and SAR analysis

The binding affinity of all ligand derivatives for *M. tuberculosis* σ^A was evaluated using MST, as shown in Tables 1–4. Overall, we did not find significant correlation between experimental







Fig. 6 Comparison of the binding poses 2a with (A) 2e, (B) 2g, (C) 2m, (D) 2n, (E) 2i, (F) 2l, and (G) 2h.

binding and the *in silico* docking score. There could be several reasons for this observation. First, pose-scoring algorithms often fail to fully account for the entropic penalties and desolvation effects associated with binding events occurring in cellular environment. More importantly, these compounds feature a tertiary amide moiety, which exists as a mixture of *cis*

and *trans* rotamers. Because the ground-state energy difference (ΔG) between these rotamers is negligible in tertiary amides, both forms are sampled during ligand preparation in the Schrödinger suite and subsequently evaluated during the docking process.¹⁹ In a biological assay, the observed affinity is a macroscopic result of the equilibrium between these two



Table 2 Compounds with substitution at the P2 position of 2a



| ID | R | Docking score (kcal mol ⁻¹) | MMGBSA score (kcal mol ⁻¹) | Binding affinity K_D (μ M) |
|----|---|---|--|-----------------------------------|
| 2a | | -4.239 | -64.28 | 2.8 ± 0.8 μ M |
| 2e | | -4.742 | -118.68 | 6.03 ± 3.81 μ M |
| 2f | | -4.107 | -57.73 | 141 ± 81 μ M |
| 2g | | -0.116 | -46.76 | 7.7 ± 4.48 μ M |
| 2h | | -3.753 | -86.37 | 162 ± 139 μ M |
| 2i | | -3.965 | -95.04 | 906 ± 165 μ M |
| 2j | | -1.234 | -57.84 | 78.5 ± 66.2 μ M |
| 2k | | -3.800 | -68.15 | 26.7 ± 21.4 μ M |
| 2l | | -4.311 | -88.31 | 65 ± 57 μ M |
| 2m | | -3.902 | -61.85 | 12.5 ± 66.2 μ M |
| 2n | | -4.049 | -75.34 | 3.5 ± 5.4 μ M |
| 2o | | -3.465 | -81.39 | 68 ± 32 μ M |



species, which may interconvert at different rates depending on the specific analogue and assay conditions. However, docking scores reflect most favourable binding for a single rotamer (whether *cis* or *trans*). Furthermore, the hydrophobic nature of the substituents resulted in poor aqueous solubility for several compounds. Nevertheless, we noted a few SAR patterns that we discuss below.


Initially, we screened analogues **2b–2d** by varying aldehyde components at the P1 region. While analogue **2b** with a 4-hydroxyphenyl ring (K_D 237.3 μM), did not show good binding, compound **2c** (K_D 0.124 μM) and **2d** (K_D 0.699 μM , Table 1) displayed significant affinity as compared to the **2a**. All three analogues displayed a different orientation than **2a** (Fig. 5A–C). The analogue **2c** featuring a pyridine ring at the P1 position displayed a distinct binding pose from **2a** and suggested strong binding with σ^A . However, the key interactions with Glu323 and Gln322 were preserved (Fig. 5B). However, we did not synthesize more analogues in this series, given the liability associated with the inflated molecular weight and higher lipophilicity due to the replacement of $-\text{H}$ (in **2a**) with other aromatic substituents.





We subsequently probed the P2 region by incorporating different acid component in the Ugi reaction. In this series, compounds **2e**, **2g**, **2m**, and **2n** displayed better binding and fostered all key interactions like **2a** (Fig. 6A–D). Compound **2g** with a *para*-nitrophenyl substitution has K_D (7.70 \pm 4.48 μM) comparable to **2a** but showed a very distinct binding pose than the latter. According to the modelling study, **2g** missed a few crucial interactions with Glu323 and Gln362 (Fig. 6B). The analogue **2m** with a smaller pyrazole at P2 showed a lower K_D

value (12.5 \pm 66.2 μM) and displayed H-bond interactions comparable to **2a**. In addition, the pyrazole ring of **2m** fostered an additional H-bond with Gln322 (Fig. 6C). The compound **2n** displayed binding (K_D 3.5 \pm 5.4 μM) comparable to **2a** but a different pose resulting in fewer interactions with the conserved residues (Fig. 6D). Other molecules in the P2 series (**2h**, **2i**, and **2l**) showed very poor binding (Table 2) with σ^A . The investigation of the binding poses revealed that compounds **2h** and **2i** with 2-chloropyridine, and 2-chlorophenyl respectively, exhibited very different binding poses lacking crucial interactions with Gln362 (Fig. 6G and E). Compound **2l** with thiazolidine showed comparable binding poses and retained interactions like **2a** (Fig. 6F). In general, except for **2a** and **2g**, the six-membered aromatic rings at P2 displayed poor binding affinity. In contrast, compounds with smaller substituents, such as a methyl group (**2e**, K_D 6.03 \pm 3.81 μM) or furyl (**2n**, K_D 3.5 \pm 5.4 μM), seem to retain strong binding.

Next, we investigated the P3 region by varying the isonitrile component of the reaction. Replacing the *tert*-butyl group of **2a** with the benzyl **2p**, cyclohexyl **2q**, and naphthyl **2r** rings was detrimental to the binding affinity (Table 3). Interestingly, the binding poses of all three analogues (**2p**, **2q** and **2r**) was similar to **2a** (Fig. 7). The compounds **2p** and **2q** retained the key interactions with all three conserved amino acids while **2r** displayed interactions with only two amino acids (Glu323 and Gln322, Fig. 7). Due to the limited availability of the commercially available isonitriles, we could not evaluate further diversity at this position.

Table 3 Compounds with substitution at the P3 position of **2a**



| ID | R | Docking score (kcal mol ⁻¹) | MMGBSA score (kcal mol ⁻¹) | Binding affinity K_D (μM) |
|-----------|---|---|--|--|
| 2a |  | -4.239 | -64.28 | 2.8 \pm 0.8 μM |
| 2p |  | -5.040 | -68.17 | 255 \pm 181 μM |
| 2q |  | -4.868 | -70.85 | 412 \pm 170 μM |
| 2r |  | -1.309 | -94.38 | 1690 \pm 1310 μM |






Fig. 7 Comparison of the binding poses 2a with 2q, 2p, and 2r.


Finally, we investigated the role of hydroxamate moiety (P4) in target engagement as suggested by the docking pose of 2a (Fig. 2D). Indeed, the replacement of hydroxamate with

hydrazide (2s) or methoxyacetamide (2t) significantly weakened binding (Table 4) underscoring the role of free $-OH$ of hydroxamate. Similarly, replacement of hydroxamate with a carboxylic acid (2v) or an ester groups (1a) also markedly reduced binding. Interestingly, converting hydroxamate into an amide in 2u resulted in a 3-fold improvement in binding (K_D 0.9 μM) compared to 2a. Notably, 2a and 2u adopt highly similar binding poses, with hydroxamate and amide groups nearly superimposable and both fostering equivalent interactions with Glu323 (Fig. 8A). In contrast, derivatives 2s, 2t, 2v, and 1a bind in a distinct orientation that lack key H-bond interactions with conserved residues. Collectively, these data indicate that the presence of an appropriately oriented H-bond donor capable of engaging Glu322 and Gln362 is a critical requirement for strong binding to σ^A , a feature retained only in 2a and 2u within this subset of compounds.

2.5 *In vitro* transcription and RNAP- σ^A holoenzyme complex assembly

Next, we evaluated all compounds for their ability to inhibit transcription. The *in vitro* transcription assay was performed using freshly purified RNAP (comprising the α , β , β' and ω subunits) along with the associated transcription factors σ^A , RbpA, and CarD to drive transcription from a DNA template with the *M. tuberculosis* rRNA AP3 promoter element. Multiple

Table 4 Compounds with substitution at the P4 position of 2a



| ID | R | Docking score (kcal mol ⁻¹) | MMGBSA score (kcal mol ⁻¹) | Binding affinity K_D (μM) |
|----|---|---|--|------------------------------------|
| 2a | | -4.239 | -64.28 | 2.8 \pm 0.8 μM |
| 2s | | -3.796 | -54.16 | 510 \pm 508 μM |
| 2t | | -2.925 | -53.38 | 420 \pm 0.9 μM |
| 2u | | -4.260 | -86.14 | 0.9 \pm 3 μM |
| 2v | | -4.042 | -38.84 | 89 \pm 0.01 μM |
| 1a | | -4.042 | -59.26 | 1200 \pm 0.5 μM |






Fig. 8 Comparison of the binding poses of 2a with (A) 2u, (B) 2t & 2s, (C) 2v, and (D) 1a.

protein preparations were evaluated to obtain an enzyme sample that was free from the *E. coli* σ^{70} contaminant. Only batches of freshly purified enzyme that did not show any transcript in the absence of σ^A in the *in vitro* transcription assays were subsequently used for the assays to evaluate effect of ligand binding. Synthesized RNA transcripts were quantified using the fluorescent RiboGreen® reagent, which selectively binds RNA. A decrease in fluorescence intensity relative to the control indicated inhibition of transcription by the test compounds. A critical step in this context involves DNase treatment to the reaction mixture to ensure that there is no

contamination due to traces of the promoter DNA template. As expected, no transcript was detected in the absence of rNTPs, confirming that the assay only reported on the mRNA formed due to RNAP activity (Fig. 9A and B). The well characterized antimycobacterial therapeutic agent, rifampicin (maintained at 1 mM), served as a positive control and was seen to completely abolish transcript formation. It is important to reiterate in this context that rifampicin is a competitive inhibitor of RNAP as opposed to the compounds evaluated in this study that are protein–protein interaction inhibitors.






Fig. 9 Transcription inhibition by protein–protein interaction inhibitors. (A) Normalized fluorescence intensity showing dose-dependent inhibition of transcription *in vitro* by compound **2a** (B) *In vitro* transcription assays of selected σ^A binders were evaluated at a fixed concentration.

As expected, compound **2a** displayed dose-dependent inhibition of transcription indicating with almost 50% inhibition at 500 μM and complete inhibition at 1 mM concentration (Fig. 9A). Evaluation of other analogues in the same assay

highlighted **2u** as another potent inhibitor of transcript formation (1 mM concentration, Fig. 2B) correlating well with its strong binding affinity (Table 4). In contrast, compounds such as **2b**, which showed weak binding, and others like **2c**, **2d**,




Fig. 10 *In vitro* screening of compounds against *M. tuberculosis* and *S. aureus*. (A and B) Image of the 96-well plate showing effect of compounds on *M. tuberculosis* H37Rv (A) and *S. aureus* (B) growth after 10 days and 48 h of incubation, respectively (top). Compounds were screened at 250 μM in (A) and 100 μM in (B) according to the scheme shown in the table (bottom). (C) Growth inhibition of *S. aureus* was determined in a 96-well plate in the presence of different concentrations of the active inhibitor (**2u**) varying from 100–0.10 μM , according to a scheme shown in the table (bottom). Image of the plate captured after 48 h of incubation reveals **2u** inhibits *S. aureus* growth at an MIC of 50 μM (top). (D) Examination of **2u** reveals complete inhibition of growth at 50 μM and 100 μM concentrations (with LoD <10 CFU) in comparison to untreated (UT) bacteria, thus indicating a bactericidal effect against *S. aureus*. DMSO and UT bacteria were simultaneously used as the vehicle and the negative controls, respectively.



2l, **2p** and **2q**, despite having relatively better binding profiles, did not produce a notable reduction in transcription. Interestingly, derivatives with substitutions at positions P2 and P3, notably **2m** and **2r**, exhibited moderate transcription inhibition of up to 50% (Fig. 9B).

To determine if the observed transcriptional inhibition is due to the direct disruption of the RNAP- σ^A interaction, we employed MST to quantify the binding affinity (K_D) of the holoenzyme complex. Under baseline conditions (5% DMSO), σ^A bound to RNAP with an apparent K_D of 109 ± 50 nM (Fig. S3A and Table S1). Pre-incubation with the negative control **2p** (Table 3) resulted in a comparable binding affinity (K_D of 143 ± 22 nM, Fig. S3B and Table S1). In contrast, the introduction of compound **2u** led to a marked decrease in binding strength, with the apparent K_D increasing to 1.78 ± 2.7 μ M. This represents an approximately 16-fold reduction in binding affinity relative to the untreated control. These results together with inhibition of transcription in the *in vitro* assay (Fig. 9) demonstrate that **2a** and **2u** specifically and substantially weakens the RNAP- σ^A interaction.

2.6 Antibacterial studies

Finally, we evaluated the most promising analogues **2a** and **2u** together with other analogues in whole-cell growth inhibition assays against *M. tuberculosis* (H37Rv). Initial screening showed no inhibition of mycobacterial growth at concentrations up to 50 μ M (data not shown). Given that **2a** inhibits *in vitro* transcription significantly only at 700 μ M (Fig. 9A), higher concentrations were tested. A 5% DMSO control (equivalent to that in 500 μ M compound) inhibited *M. tuberculosis* growth, so results obtained with 250 μ M compound concentrations were considered. While most of the compounds remain ineffective, a notable complete inhibition of growth was observed for analogue **2u** at 250 μ M, as assessed by visualizing the pellet formation after 10 days of incubation at 37 $^{\circ}$ C in a U-bottom 96-well plate (Fig. 10A). This data likely reflects stronger transcription inhibition by **2u** at this concentration or permeation liabilities of the polar hydroxamate moiety, which impedes passive diffusion of **2a** across membranes.^{22–24} Hydroxamates are also known to suffer hydrolytic cleavage in cellular environments, unlike the more robust amide functionality in **2u**.²⁵

To investigate whether the observed lack of antibacterial potency was a result of chemical instability, particularly regarding the hydroxamate moiety in **2a**, stability studies were conducted in phosphate-buffered saline (PBS). Both **2a** and its amide control **2u**, were monitored *via* HPLC over 48 hours. Neither compound exhibited significant degradation or changes in chromatographic profiles over 48 hours (Fig. S4), indicating sufficient chemical stability, at least under the assay conditions.

Given the pronounced structural similarity between RNAP homologues (despite sequence differences) and the conserved nature of the RNAP- σ^A binding interface across bacterial species, we also evaluated these analogues against the Gram-positive pathogen *Staphylococcus aureus*. Freshly grown *S. aureus* cultures were incubated with individual compounds at

100 μ M concentration in a U-bottom 96-well plate, and growth was assessed by visualizing pellet formation after 48 h incubation at 37 $^{\circ}$ C. Among the 18 analogues tested, only **2u** completely inhibited growth (Fig. 10B), consistent with its strong σ^A binding affinity, and potent inhibition of *in vitro* transcription as well as *M. tuberculosis* H37Rv growth. Subsequently, a minimum inhibitory concentration (MIC) was determined by incubating *S. aureus* with serial dilutions of **2u**, which revealed that **2u** inhibits growth of *S. aureus* at an MIC of 50 μ M (Fig. 10C). Most importantly, plating an aliquot of *S. aureus* treated with 50 or 100 μ M **2u** and untreated culture on LB agar plate clearly established the bactericidal effect of the inhibitor (Fig. 10D).

Notably, compound **2a**, the hydroxamate derivative of **2u**, once again proved inactive in the whole cell assay, despite comparable transcription inhibition. This could be due to ineffective binding of **2a** with *S. aureus* σ^A indicated by the docking studies discussed below (Section 2.7). Nevertheless, **2u**'s modest antibacterial potency against both pathogens validates the rational design strategy targeting the conserved RNAP- σ^A interface for the discovery of novel transcription inhibitors.

2.7 Molecular docking of 2u with σ^A of *S. aureus*

To predict binding modes, we performed molecular docking of both, **2a** and **2u**, with the σ^A of *S. aureus* (PDB 8X6F) obtained using cryo-electron microscopy.²⁶ Superimposition of *S. aureus* and *M. tuberculosis* σ^A structures enabled the identification of binding site for docking into *S. aureus* σ^A (Fig. S5A and S5B).

The docking pose of **2u** in *S. aureus* σ^A closely resembled its pose in *M. tuberculosis* σ^A (Fig. S5C vs. Fig. 8A). In both cases, the amide $-NH_2$ fostered a H-bond with Gln202 (*S. aureus* numbering; Gln362 in *M. tuberculosis*). Compound **2u** also formed an additional H-bond with the conserved residue Asp159 (Asp319 in *M. tuberculosis*). In contrast, compound **2a** adopted different orientations in the σ^A factors of both organisms (Fig. S5D vs. Fig. 8A). It lacked the H-bond with Gln202 in *S. aureus* σ^A unlike its interaction with the corresponding Gln362 in *M. tuberculosis* σ^A . However, **2a** retained a H-bond with Asp159 in *S. aureus* σ^A .

Compound **2a** also exhibited a slightly lower docking score with *S. aureus* σ^A compared to **2u** (3.03 vs. 3.30 kcal mol⁻¹). Together, this molecular modeling study supports the stronger interaction of **2u** with *S. aureus* σ^A than **2a**, consistent with its superior antibacterial activity against *S. aureus*.

Overall, the data suggest that both **2a** and **2u** remain stable under assay conditions and their poor cellular activity may be due to the reduced passive permeation. This is especially true for *M. tuberculosis* where the notoriously impermeable, lipid-rich mycomembrane pose a well-documented challenge in drug discovery.²⁷ In contrast to **2a**, **2u** seems to maintain similar binding pose in σ^A factors of both *S. aureus* and *M. tuberculosis*.

3. Conclusions

In summary, this is the first report describing a rational approach for the design of non-competitive inhibitors of *M.*



tuberculosis transcription by targeting RNAP- σ^A interface. Using sequence alignment and mutational analysis we established the σ^A residues important for interacting with RNAP. We systematically explored a focussed MCR-based library (URDL), occupying protein-protein inhibitor chemical space, for the identification of σ^A binders. SBVS approach combined with an efficient synthetic protocol expedited hit identification yielding a hydroxamate compound **2a** (K_D 2.8 μ M). The MCR modularity allowed for rapid SAR exploration across P1–P4 regions, generating 22 analogues in 1–2 steps. Ligand binding and *in vitro* transcription assays revealed hydroxamate (**2a**) and amide (**2u**) as potent RNAP- σ^A disruptors, with nearly identical docking poses with significant interactions with the conserved σ^A residues. Unfortunately, the whole-cell activity was not significant against *M. tuberculosis*, likely due to restricted penetration across the mycomembrane. Nonetheless, amide **2u** exhibited bactericidal activity against *S. aureus* (MIC 50 μ M), displaying broader applicability of this scaffold for antimicrobial development.

While inhibitors of RNAP- σ^A interface of other bacterial species are reported, a direct comparison of these inhibitors with our series is not possible given the inherent differences in the transcription machineries of *M. tuberculosis* and other bacterial species. Structurally, our lead inhibitors **2a** and **2u** are distinct than the other reported inhibitors. Nonetheless, these compounds show similarity to reported inhibitors in terms of higher micromolar concentrations required to inhibit the growth of *S. aureus* in culture.^{11,12}

Overall, this series is a viable starting point for the development of broad-spectrum bacterial RNAP inhibitors. The facile, two-step synthesis demonstrated here highlights the utility of MCRs in accelerating the drug discovery cycle. Future efforts will prioritize amide-based analogues to improve cellular permeability and antibacterial potency. Additionally, combination studies evaluating potential synergy with competitive RNAP inhibitors, such as rifampicin, remains to be examined.

Conflicts of interest

Authors declare no financial or non-financial interests that are directly or indirectly related to the work submitted for publication.

Abbreviations

| | |
|-------|---|
| BPB | Bromophenol blue |
| CarD | Caspase recruitment domains |
| DMSO | Dimethyl sulfoxide |
| DTT | Dithiothreitol |
| EDTA | Ethylenediaminetetraacetic acid |
| K_D | Dissociation constant |
| HEPES | 2-[4-(2-Hydroxyethyl)piperazin-1-yl]ethanesulfonic acid |
| HPLC | High-performance liquid chromatography |
| HRMS | High-resolution mass spectrometry |
| HTVS | High throughput virtual screening |

| | |
|--------|--|
| MIC | minimum inhibitory concentration |
| MMGBSA | Molecular mechanics with generalised born and surface area |
| MST | Microscale thermophoresis |
| NMR | Nuclear magnetic resonance |
| PAGE | Polyacrylamide gel electrophoresis |
| RbpA | RNA polymerase-binding protein A |
| RNAP | RNA polymerase |
| rNTPs | A ribonucleotide triphosphate |
| SAR | Structure-activity relationship |
| SLS | Sodium lauryl sulphate |
| TLC | Thin layer chromatography |
| URDL | Ugi reaction-derived library |
| UT | Untreated |

Data availability

The data supporting this article has been included in the main article and as part of supplementary information (SI). Supplementary information: Fig. S1–S5, Tables S1 and S2, detailed computational and experimental methodologies, and all spectral data (NMR, HRMS, *etc.*) of final compounds. See DOI: <https://doi.org/10.1039/d6ra00442c>.

Acknowledgements

This work is supported by the funding from the Indian Council of Medical Research (ICMR), New Delhi, India (Grant No. 67/3/2020-DDI/BMS). Funding support from the THSTI core to Ms. Eeba and NA is acknowledged. MT and MK acknowledge the fellowship provided by BITS Pilani. We acknowledge DST, New Delhi, India, for sponsoring the HRMS and LC-MS facility at BITS Pilani, Pilani, under the FIST program. We thank Dr. Bhabatosh Das at the Translational Health Science and Technology Institute, Faridabad for providing pathogenic *S. aureus* strain.

References

- W. Lin, S. Mandal, D. Degen, Y. Liu, Y. W. Ebright, S. Li, Y. Feng, Y. Zhang, S. Mandal, Y. Jiang, S. Liu, M. Gigliotti, M. Talaue, N. Connell, K. Das, E. Arnold and R. H. Ebright, *Mol. Cell*, 2017, **66**, 169–179.
- D. X. Zhu, A. L. Garner, E. A. Galburt and C. L. Stallings, *Proc. Natl. Acad. Sci. U. S. A.*, 2019, **116**, 13573–13581.
- J. C. Perez and E. A. Groisman, *Cell*, 2009, **138**, 233–244.
- F. Stephanie, U. Sumo and F. Tambunan, *Life*, 2022, **12**, 1–21.
- N. Woodford and M. J. Ellington, *Clin. Microbiol. Infect.*, 2006, **13**, 5–18.
- B. P. Goldstein, *J. Antibiot.*, 2014, **67**, 625–630.
- E. André, L. Bastide, P. Villain-guillot, J. Latouche, J. Rouby and J. Leonetti, *Assay Drug Dev. Technol.*, 2004, **2**, 629–635.
- D. E. Scott, A. R. Bayly, C. Abell and J. Skidmore, *Nat. Rev. Drug Discovery*, 2016, **15**, 533–550.
- C. M. Labbé, M. A. Kuenemann, B. Zarzycka, G. Vriend, G. A. F. Nicolaes, D. Lagorce, M. A. Miteva, B. O. Villoutreix and O. Sperandio, *Nucleic Acids Res.*, 2016, **44**, D542–D547.



- 10 C. Ma, X. Yang and P. J. Lewis, *Microbiol. Mol. Biol. Rev.*, 2016, **80**, 139–160.
- 11 C. Ma, X. Yang, H. Kandemir, M. Mielczarek, E. B. Johnston, R. Griffith, N. Kumar and P. J. Lewis, *ACS Chem. Biol.*, 2013, **8**, 1972–1980.
- 12 C. Ma, X. Yang and P. J. Lewis, *ACS Infect. Dis.*, 2016, **2**, 39–46.
- 13 J. Ye, A. J. Chu, R. Harper, S. T. Chan, T. L. Shek, Y. Zhang, M. Ip, M. Sambir, I. Artsimovitch, Z. Zuo, X. Yang and C. Ma, *J. Med. Chem.*, 2020, **63**, 7695–7720.
- 14 A. Feklistov, B. D. Sharon, S. A. Darst and C. A. Gross, *Annu. Rev. Microbiol.*, 2014, **68**, 357–376.
- 15 M. Tandi, N. Tripathi, A. Gaur, B. Gopal and S. Sundriyal, *Mol. Divers.*, 2024, **28**, 37–50.
- 16 I. Ugi and C. Steinbrückner, *Angew. Chem.*, 1960, **72**, 267–268.
- 17 M. Tandi, V. Sharma, B. Gopal and S. Sundriyal, *RSC Adv.*, 2025, **15**, 1447–1489.
- 18 M. Tandi and S. Sundriyal, *J. Indian Chem. Soc.*, 2021, **98**, 100106.
- 19 D. Diedrich, A. Hamacher, C. G. W. Gertzen, L. A. Alves Avelar, G. J. Reiss, T. Kurz, H. Gohlke, M. U. Kassack and F. K. Hansen, *Chem. Commun.*, 2016, **52**, 3219–3222.
- 20 G. Joshi, S. Kalra, U. Prasad, P. Sharma, P. Kumar, S. Amrutkar, A. J. Ansari, S. Kumar, A. Sharon and S. Sharma, *Bioorg. Chem.*, 2020, **94**, 103409.
- 21 B. Yoo and K. Kirshenbaum, *Curr. Opin. Chem. Biol.*, 2008, **12**, 714–721.
- 22 S. Shen and A. P. Kozikowski, *ChemMedChem*, 2016, **11**, 15–21.
- 23 S. Kesharwani, N. Eeba, M. Tandi, N. Agarwal and S. Sundriyal, *RSC Adv.*, 2024, **14**, 27530–27554.
- 24 S. Kesharwani and S. Sundriyal, *Eur. J. Med. Chem.*, 2021, **213**, 113055.
- 25 P. Hermant, D. Bosc, C. Piveteau, R. Gealageas, B. Lam, C. Ronco, M. Roignant, H. Tolojanahary, L. Jean, P. Y. Renard, M. Lemdani, M. Bourotte, A. Herledan, C. Bedart, A. Biela, F. Leroux, B. Deprez and R. Deprez-Poulain, *J. Med. Chem.*, 2017, **60**, 9067–9089.
- 26 L. Yuan, Q. Liu, L. Xu, B. Wu and Y. Feng, *Nat. Commun.*, 2024, **15**, 4850.
- 27 S. M. Batt, D. E. Minnikin and G. S. Besra, *Biochem. J.*, 2020, **447**, 1983–2006.

